L Montus Oral Suspension is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg per 5 ml, formulated for the management of allergic conditions in pediatric patients. Levocetirizine is a selective, second-generation antihistamine that acts as a potent H1 receptor antagonist, effectively reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast is a leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor, thereby preventing bronchoconstriction, inflammation, and edema in the airways. The synergistic action of these two agents provides comprehensive relief from allergic rhinitis and asthma-related symptoms, improving patient quality of life. L Montus Oral Suspension is indicated for children requiring both antihistaminic and leukotriene receptor antagonist therapy, offering ease of administration and accurate dosing. The suspension should be used under medical supervision, with dosage adjusted according to age and clinical response. Common side effects may include headache, gastrointestinal discomfort, and fatigue. Contraindications include hypersensitivity to any component of the formulation. This combination therapy is a valuable option in pediatric allergy management, combining efficacy and convenience in a single oral suspension.